EPRX
Eupraxia Pharmaceuticals Inc
NASDAQ · Biotechnology
$8.35
-0.11 (-1.30%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 121.08M | 121.80M | 129.11M |
| Net Income | -20,292,332 | -19,070,968 | -17,081,441 |
| EPS | — | — | — |
| Profit Margin | -16.8% | -15.7% | -13.2% |
| Rev Growth | +21.7% | +19.1% | -8.5% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 61.96M | 66.90M | 72.48M |
| Total Equity | 382.98M | 378.70M | 384.55M |
| D/E Ratio | 0.16 | 0.18 | 0.19 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -26,386,283 | -29,891,368 | -27,935,877 |
| Free Cash Flow | -23,062,869 | -20,449,670 | -23,278,243 |